GDF-15 A potential Biomarker of Diabetic Nephropathy in Iraq Patients with Chronic Kidney Disease
doi.org/10.26538/tjnpr/v4i12.9
Keywords:
Diabetic nephropathy, GDF-15, CKD, Anemia CKDAbstract
Growth differentiation factor-15 (GDF-15) expression increase exposure to tissue injury and has recently emerged as a useful biomarker for multiple diseases. This study is aimed at detecting serum GDF-15 in patients with chronic kidney disease (CKD) and assessing its value in the early diagnosis of diabetic nephropathy (DN). This cross-sectional study, involved a total of 60
patients with CKD aged 15-65 years, selected according to their albumin creatinine ratio (ACR): >30 mg/g (DN 42), and ACR <30 mg/g (without DN 18), patients were compared with 28 healthy participants. Serum GDF-15 level, hematological, and biochemical parameters were measured. In the DN group, levels of GDF-15, C-reactive protein (CRP), urea, and creatinine were significantly higher, while RBCs, Hb, and GFR were significantly lower (p < 0.05) in comparison with CKD non-DN group. GDF-15 was significantly negatively correlated with RBCs (R2=0.548), Hb (R2=0.559), and GFR (R2=0.466), while it was positively associated withCRP (R2=0.532). The receiver operating characteristic (ROC) curve to assess value of GDF-15 indicated AUC 87.7% ± 0.045 (95% CI 0.78–0.99, p<0.0001, 83.2-22.2% sensitivity and specificity). In multivariate analysis, GDF-15 is independently predictive for diagnosing DN (OR=1.01, 95% CI: 1.00-1.03, P=0.009). Furthermore, each of Hb, GFR, and CRP was found a predictor of GDF-15, (β =-0.42, 2.35, and 0.26). In conclusion, GDF-15 represents a risk biomarker in CKD patients with DN with associated anaemia and inflammation more than in CKD without DN. Additionally, GDF-15 can be a predictive risk stratification factor for achieving the end stage of diabetic kidney disease.
References
Gaidan AM, Al-husseiny IA. Red Cell Distribution Width and Neutrophil-Lymphocyte Ratio as Markers for Diabetic Nephropathy. Trop J Nat Prod Res. 2020; 4(8):338-342.
Silva EFF, Ferreira CMM, De Pinho L. Risk factors and complications in type 2 diabetes outpatients. Rev Assoc Med Bras. 2017; 63(7):621-627.
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, De Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic Kidney Disease: A Report from an ADA Consensus Conference.
Am J Kidney Dis. 2014; 64(4):510-533.
Tsai VWW, Husaini Y, Sainsbury A, Brown DA, Breit SN. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. Cell Metab. 2018; 28(3):353-368.
Gurley SB, Ghosh S, Johnson SA, Azushima K, Sakban RB, George SE, Maeda M, Meyer TW, Coffman TM. Inflammation and immunity pathways regulate genetic susceptibility to diabetic nephropathy. Diabetes. 2018; 67(10):2096-2106.
Kim JS, Kim S, Won CW, Jeong KH. Association between plasma levels of growth differentiation factor-15 and renal function in the elderly: Korean frailty and aging cohort study. Kidney Blood Press Res. 2019; 44(3):405-414.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012; 2(4):279–335.
Mishra D, Prakash S, Sahoo D, Ray G, Routray S, Das P MS. Prevalence of A2 and A2B subgroups along with antiA1 antibody in patients and donor population and its clnical significance. J Appl Hematol. 2020; 11(3):112-115.
Cernaro V, Coppolino G, Magna S, Magna S, Cernaro V, Lacquaniti A, Santoro D, Buemi A, Buemi M. Erythropoiesis and chronic kidney disease – related anemia : From physiology to new therapeutic advancements Erythropoiesis and chronic kidney disease – related
anemia : From physiology to new therapeutic advancements. Physiol to new Ther Adv. 2019; 39(2):427-460.
Almousawi AS, Sharba IR. Erythroferrone Hormone a Novel Biomarker is associated with Anemia and Iron Overload in Beta Thalassemia Patients . Erythroferrone Hormone a Novel Biomarker is associated with Anemia and Iron Overload in Beta Thalassemia. J Phys Conf Ser. 2019; 1294:062045.
Palaka E, Grandy S, Van Haalen H, McEwan P, Darlington O. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes - A Systematic Literature Review. Int J Nephrol. 2020; 1:21.
Ye Y, Liu H, Chen Y, Zhang Y, Li S, Hu W, Yang R, Zhang Z, Lv L, Liu X. Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials. Ren Fail. 2018; 40(1):671-679.
Tsai MH, Leu JG, Fang YW, Liou HH. High fibroblast growth factor 23 levels associated with low hemoglobin levels in patients with chronic kidney disease stages 3 and 4. Med (United States). 2016; 95(11):e3049.
Risso MA, Sallustio S, Sueiro V, Bertoni V, GonzalezTorres H, Musso CG. The importance of tubular function in chronic kidney disease. Int J Nephrol Renovasc Dis. 2019; 12: 257–262.
Ciovicescu F, Vesa ŞC, Rǎdulescu D, Crişan S, Duncea C. Haemodialysis-induced electrolyte variation (serum calcium, magnesium and bicarbonate) and intradialytic heart rhythm disorders. Hum Vet Med. 2014; 6(1):11-14.
Hassen HF, Al-Lami MQD, Al-Saedi AJH. Evaluation some Biochemical Levels in Patients undergoing Hemodialysis in Baghdad Governorate. J Adv Lab Res Biol. 2018; 9(2):50-57.
Jehn U, Schütte-Nütgen K, Henke U, Bautz J, Pavenstädt H, Suwelack B, Reuter S. Prognostic Value of Growth Differentiation Factor 15 in Kidney Donors and Recipients. J Clin Med. 2020; 9(5):1333.
Li M, Duan L, Cai YL, Li HY, Hao BC, Chen JQ, Liu H Bin. Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol. 2020; 19(1):1-23.
Carlsson AC, Nowak C, Lind L, Östgren CJ, Nyström FH, Sundström J, Carrero JJ, Riserus U, Ingelsson E, Fall T,Ärnlöv J. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020; 1(125):37-43.
Desmedt S, Desmedt V, De Vos L, Delanghe JR, Speeckaert R, Speeckaert MM. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci. 2019; 56(5):333-350.
Nair V, Robinson-Cohen C, Smith MR, Bellovich KA, Bhat ZY, Bobadilla M, Brosius F, De Boer IH, Essioux L, Formentini I, Gadegbeku CA, Gipson D, Hawkins J, Himmelfarb J, Kestenbaum B, et al. Growth differentiation factor-15 and Risk of CKD progression. J Am Soc Nephrol. 2017; 28(7):2233-2240.
Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M, Wollert KC. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: Results from the XENDOS trial. Eur JEndocrinol. 2012; 167(5):671-678.
Lukaszyk E, Lukaszyk M, Koc-Zorawska E, BodzentaLukaszyk A, Malyszko J. GDF‑15, iron, and inflammation in early chronic kidney disease among elderly patients. Int Urol Nephrol. 2016; 48(6):839-844.
Hong JH, Choi YK, Min BK, Park KS, Seong K, Lee IK, Kim JG. Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment. Diabetes Res Clin Pract. 2015; 109(1):64-70.
Dostálová I, Roubíček T, Bártlová M, Mráz M, Lacinová Z, Haluzíková D, Kaválková P, Matoulek M, Kasalický M,Haluzík M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: The influence of very low calorie diet. Eur J Endocrinol. 2009; 161(3):397-404.
Eggers KM, Kempf T, Wallentin L, Wollert KC, Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in communitydwelling elderly individuals. Clin Chem. 2013; 59(7):1091- 1098.
Ham YR, Song CH, Bae HJ, Jeong JY, Yeo MK, Choi DE, Na KR, Lee KW. Growth differentiation factor-15 as a predictor of idiopathic membranous nephropathy progression: A retrospective study. Dis Markers. 2018; 2018.
Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care. 2010; 3(7):1567-1572.
Zhang M, Pan K, Liu Q, Zhou X, Jiang T, Li Y. Growth differentiation factor 15 may protect the myocardium from no-reflow by inhibiting the inflammatory-like response that predominantly involves neutrophil infiltration. Mol Med Rep. 2016; 13(1):623-632.
Luyckx VA, Tuttle KR, Garcia-Garcia G, Gharbi MB, Heerspink HJL, Johnson DW, Liu ZH, Massy ZA, Moe O, Nelson RG, Sola L, Wheeler C, White SL. Reducing major risk factors for chronic kidney disease. Kidney Int Suppl. 2017; 7(2):71-87.
Mikhali A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Issc H, Bhandari S. Clinical Practice Guideline Anaemia of Chronic Kidney Disease. Anaemia Chronic Kidney Dis. 2017; 2017:7-49.
Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010; 17:184–190.
Breit SN, Carrero JJ, Tsai VW-W, Yagoutifam N, Luo W, Kuffner T, Bauskin AR, Wu L, Jiang L, Barany P, Heimburger O, Murikami M-A, Apple FS, Marquis CP, Macia L, et al. Macrophage inhibitory cytokine-1 (MIC- 1/GDF15) and mortality in end-stage renal disease.Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2012; 27(1):70-75.
Banaszkiewicz, Małyszko, Vesole, Woziwodzka, Jurczyszyn, Żórawski, Krzanowski, Małyszko, Batko, Kuźniewski, Krzanowska. New Biomarkers of Ferric Management in Multiple Myeloma and Kidney DiseaseAssociated Anemia. J Clin Med. 2019; 8(11):1828.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
